Dengue drug discovery

Pei-Yong Shi, Zheng Yin, Shahul Nilar, Thomas H. Keller

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Dengue is the most common viral disease in the tropical and subtropical regions of the world. At present no vaccine or antiviral drugs are available to treat a dengue infection, which leaves supportive care in hospitals as the only available treatment option. Since dengue epidemics often put great strain on healthcare systems, there is an urgent need for novel strategies to combat this disease. The development of vaccines for dengue is complicated by the presence of four different serotypes, which has increased the importance of antiviral drug discovery. In the past 10 years, dengue has changed from a disease that was basically unknown to drug discovery scientists into a vibrant field of research for both biologists and chemists. In this chapter, we will review the different drug targets that have been identified for dengue and critically assess the progress that has been made in antiviral drug discovery. While these efforts have not yet resulted in a clinical development candidate, the progress has been impressive, considering the limited resources. Nevertheless, a concerted effort is required to identify drug candidates for the most promising targets, dengue NS3 protease and dengue NS5 polymerase.

Original languageEnglish (US)
Title of host publicationTopics in Medicinal Chemistry
Pages243-276
Number of pages34
Volume7
DOIs
StatePublished - 2011
Externally publishedYes

Publication series

NameTopics in Medicinal Chemistry
Volume7
ISSN (Print)18622461
ISSN (Electronic)1862247X

Fingerprint

Dengue
Drug Discovery
Antiviral Agents
Dengue Vaccines
Virus Diseases
Pharmaceutical Preparations
Peptide Hydrolases
Vaccines
Delivery of Health Care
Infection
Research

Keywords

  • Dengue
  • E-protein
  • Flavivirus
  • Glucosidase
  • NS3 protease
  • NS5 polymerase

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Shi, P-Y., Yin, Z., Nilar, S., & Keller, T. H. (2011). Dengue drug discovery. In Topics in Medicinal Chemistry (Vol. 7, pp. 243-276). (Topics in Medicinal Chemistry; Vol. 7). https://doi.org/10.1007/7355_2011_16

Dengue drug discovery. / Shi, Pei-Yong; Yin, Zheng; Nilar, Shahul; Keller, Thomas H.

Topics in Medicinal Chemistry. Vol. 7 2011. p. 243-276 (Topics in Medicinal Chemistry; Vol. 7).

Research output: Chapter in Book/Report/Conference proceedingChapter

Shi, P-Y, Yin, Z, Nilar, S & Keller, TH 2011, Dengue drug discovery. in Topics in Medicinal Chemistry. vol. 7, Topics in Medicinal Chemistry, vol. 7, pp. 243-276. https://doi.org/10.1007/7355_2011_16
Shi P-Y, Yin Z, Nilar S, Keller TH. Dengue drug discovery. In Topics in Medicinal Chemistry. Vol. 7. 2011. p. 243-276. (Topics in Medicinal Chemistry). https://doi.org/10.1007/7355_2011_16
Shi, Pei-Yong ; Yin, Zheng ; Nilar, Shahul ; Keller, Thomas H. / Dengue drug discovery. Topics in Medicinal Chemistry. Vol. 7 2011. pp. 243-276 (Topics in Medicinal Chemistry).
@inbook{fbf97ad9d4da497ca156ba010445980c,
title = "Dengue drug discovery",
abstract = "Dengue is the most common viral disease in the tropical and subtropical regions of the world. At present no vaccine or antiviral drugs are available to treat a dengue infection, which leaves supportive care in hospitals as the only available treatment option. Since dengue epidemics often put great strain on healthcare systems, there is an urgent need for novel strategies to combat this disease. The development of vaccines for dengue is complicated by the presence of four different serotypes, which has increased the importance of antiviral drug discovery. In the past 10 years, dengue has changed from a disease that was basically unknown to drug discovery scientists into a vibrant field of research for both biologists and chemists. In this chapter, we will review the different drug targets that have been identified for dengue and critically assess the progress that has been made in antiviral drug discovery. While these efforts have not yet resulted in a clinical development candidate, the progress has been impressive, considering the limited resources. Nevertheless, a concerted effort is required to identify drug candidates for the most promising targets, dengue NS3 protease and dengue NS5 polymerase.",
keywords = "Dengue, E-protein, Flavivirus, Glucosidase, NS3 protease, NS5 polymerase",
author = "Pei-Yong Shi and Zheng Yin and Shahul Nilar and Keller, {Thomas H.}",
year = "2011",
doi = "10.1007/7355_2011_16",
language = "English (US)",
isbn = "9783642234866",
volume = "7",
series = "Topics in Medicinal Chemistry",
pages = "243--276",
booktitle = "Topics in Medicinal Chemistry",

}

TY - CHAP

T1 - Dengue drug discovery

AU - Shi, Pei-Yong

AU - Yin, Zheng

AU - Nilar, Shahul

AU - Keller, Thomas H.

PY - 2011

Y1 - 2011

N2 - Dengue is the most common viral disease in the tropical and subtropical regions of the world. At present no vaccine or antiviral drugs are available to treat a dengue infection, which leaves supportive care in hospitals as the only available treatment option. Since dengue epidemics often put great strain on healthcare systems, there is an urgent need for novel strategies to combat this disease. The development of vaccines for dengue is complicated by the presence of four different serotypes, which has increased the importance of antiviral drug discovery. In the past 10 years, dengue has changed from a disease that was basically unknown to drug discovery scientists into a vibrant field of research for both biologists and chemists. In this chapter, we will review the different drug targets that have been identified for dengue and critically assess the progress that has been made in antiviral drug discovery. While these efforts have not yet resulted in a clinical development candidate, the progress has been impressive, considering the limited resources. Nevertheless, a concerted effort is required to identify drug candidates for the most promising targets, dengue NS3 protease and dengue NS5 polymerase.

AB - Dengue is the most common viral disease in the tropical and subtropical regions of the world. At present no vaccine or antiviral drugs are available to treat a dengue infection, which leaves supportive care in hospitals as the only available treatment option. Since dengue epidemics often put great strain on healthcare systems, there is an urgent need for novel strategies to combat this disease. The development of vaccines for dengue is complicated by the presence of four different serotypes, which has increased the importance of antiviral drug discovery. In the past 10 years, dengue has changed from a disease that was basically unknown to drug discovery scientists into a vibrant field of research for both biologists and chemists. In this chapter, we will review the different drug targets that have been identified for dengue and critically assess the progress that has been made in antiviral drug discovery. While these efforts have not yet resulted in a clinical development candidate, the progress has been impressive, considering the limited resources. Nevertheless, a concerted effort is required to identify drug candidates for the most promising targets, dengue NS3 protease and dengue NS5 polymerase.

KW - Dengue

KW - E-protein

KW - Flavivirus

KW - Glucosidase

KW - NS3 protease

KW - NS5 polymerase

UR - http://www.scopus.com/inward/record.url?scp=80054899372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054899372&partnerID=8YFLogxK

U2 - 10.1007/7355_2011_16

DO - 10.1007/7355_2011_16

M3 - Chapter

AN - SCOPUS:80054899372

SN - 9783642234866

VL - 7

T3 - Topics in Medicinal Chemistry

SP - 243

EP - 276

BT - Topics in Medicinal Chemistry

ER -